Results 261 to 270 of about 5,247,281 (389)

Coronary Slow Flow and No‐Reflow During Percutaneous Coronary Intervention: Contemporary Insights Into Imaging‐Guided Prediction, Prevention, and Management

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Coronary slow flow (SF) and no‐reflow (NR) are clinically significant complications of percutaneous coronary intervention (PCI), particularly in ST‐segment elevation myocardial infarction (STEMI) and saphenous vein graft (SVG) interventions. Angiographically defined as impaired myocardial perfusion despite restored epicardial patency, SF/NR ...
Bharat Khialani   +5 more
wiley   +1 more source

Extremity Function After Transfemoral Transcatheter Aortic Valve Implantation: A TAVI XS Sub‐Study

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Physical decline after transcatheter aortic valve implantation (TAVI) is associated with worse outcomes. However, data on post‐TAVI extremity function are limited. This sub‐study of the TAVI XS trial aimed to assess extremity function after transfemoral TAVI, evaluate functional decline, compare outcomes between upper‐and lower ...
Geert A. A. Versteeg   +20 more
wiley   +1 more source

Feasibility and Safety of the ETcath200 Robotic PCI System for Complex Coronary Lesions: A Prospective Single‐Center Study

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background International robotic‐assisted PCI platforms such as CorPath 200 and CorPath GRX have demonstrated procedural safety and efficacy but are limited by the absence of real‐time tactile feedback and cumbersome device exchange. The ETcath200, the first domestically developed robotic PCI system in China, introduces guidewire force‐sensing
Jing Yang   +8 more
wiley   +1 more source

Self‐Management Interventions in Young Adults (18–30 Years) With Type 1 Diabetes, Sickle Cell Disease, and Inflammatory Bowel Disease: A Scoping Review

open access: yesChronic Diseases and Translational Medicine, EarlyView.
ABSTRACT Fluctuating chronic conditions (FCC) in young adults aged 18–30 years, such as type 1 diabetes (T1D), sickle cell disease (SCD), and inflammatory bowel disease (IBD), present unique self‐management challenges due to unpredictable symptom patterns that disrupt daily life.
Reham Almabadi   +3 more
wiley   +1 more source

Counseling Professionals’ Perspectives on AI Integration in Education and Supervision: A Concept Mapping Study

open access: yesCounselor Education and Supervision, EarlyView.
ABSTRACT The rapid emergence of artificial intelligence (AI) has raised important questions about how new technologies will shape professional norms and practices in counseling. The purpose of this study was to understand how counseling professionals expect AI to be integrated into counselor education and supervision (CES).
Hank Crofford, Elif Bor, Gülşah Kemer
wiley   +1 more source

Early‐Life Clinical Factors Shape Cerebellar Structure in Preterm‐Born Children

open access: yesAnnals of the Child Neurology Society, EarlyView.
ABSTRACT Objective Preterm birth alters typical brain development due to complex exposures related to neonatal illness, pain management, and brain injury. Despite an increased understanding of neonatal brain injury on developmental outcomes, the association of cerebellar maturation with school‐age motor and cognitive function remains incompletely ...
Victoria Rapos   +6 more
wiley   +1 more source

Population Pharmacokinetics of Clesrovimab in Preterm and Full‐Term Infants

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Clesrovimab is a half‐life extended monoclonal antibody targeting the respiratory syncytial virus fusion protein. Three studies (phase Ib/IIa [MK‐1654‐002], phase IIb/III [CLEVER], and phase III [SMART]) were conducted to evaluate the efficacy, safety, and pharmacokinetics (PK) of clesrovimab in infants.
Ziheng Hu   +8 more
wiley   +1 more source

Population Pharmacokinetic and Exposure‐Efficacy Analysis of Baloxavir Marboxil for Influenza Treatment and Post‐Exposure Prophylaxis in Children

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Baloxavir acid (baloxavir), the active metabolite of the prodrug baloxavir marboxil, is a selective inhibitor of the influenza virus cap‐dependent endonuclease. The population pharmacokinetic (popPK) profile of baloxavir in adults/adolescents has been described previously.
Sylvie Retout   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy